ORIC
NASDAQOric Pharmaceuticals Inc.
Price$7.52-0.82 (-9.78%)
01:30 PM07:45 PM
News · 26 weeks51-82%
2025-12-142026-06-07
Mix1890d
- Other11(61%)
- SEC Filings4(22%)
- Earnings2(11%)
- Analyst1(6%)
Latest news
25 items- PRORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the "Grant Date"), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock opti
- PRORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in June: Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 3, 2026, at 11:40 a.m. ET. Management will also be participating in one-on-one meetings. Goldman Sachs 47th Annual Global Healthcare Conference – Participating in a fireside chat on Tuesday, June 9, 2026, at 8:00 a.m. ET. Management will also be participating in one
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
- SECSEC Form SCHEDULE 13G filed by Oric Pharmaceuticals Inc.SCHEDULE 13G - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
- ANALYSTORIC Pharmaceuticals upgraded by Goldman with a new price targetGoldman upgraded ORIC Pharmaceuticals from Neutral to Buy and set a new price target of $15.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
- SECSEC Form 10-Q filed by Oric Pharmaceuticals Inc.10-Q - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
- SECOric Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
- PRORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational UpdatesAnnounced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzimetostat data in post-abiraterone mCRPC supporting potential best-in-disease profile, including a highly differentiated safety profile and landmark rPFS consistent with competitor PRC2 inhibitor and substantially better than standard of care therapies in mCRPC Reported early rinzimetostat data in post-AR inhibitor mCRPC, demonstrating promising durability and reinforcing rinzimetostat's potential to restore and sustain the benefit derived from AR inhibitors Anticipate rinzimetostat program up
- PRORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2026 (the "Grant Date"), ORIC granted a total of 216,000 non-qualified stock options and 35,000 restricted stock units to four new non-executive employees who began their employment with ORIC in April 2026. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock o
- SECSEC Form DEFA14A filed by Oric Pharmaceuticals Inc.DEFA14A - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
- SECSEC Form DEF 14A filed by Oric Pharmaceuticals Inc.DEF 14A - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
- PRORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual MeetingSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting the potential of rinzimetostat (ORIC-944), a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer. The posters can be found in the publication section of ORIC's website here. "Our research continues to show the therapeutic potential of PRC2 inhibition across the prostate cancer dise
- PRORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2026 (the "Grant Date"), ORIC granted a total of 80,000 non-qualified stock options and 15,000 restricted stock units to one new non-executive employee who began their employment with ORIC in March 2026. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock
- PRORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease ProfileRinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026 At a median follow-up of ~5 months, landmark 5-month rPFS of 84% is consistent with competitor PRC2 inhibitor and substantially better than standard of care therapies in mCRPC Highly differentiated, potential best-in-disease safety profile, with significantly lower frequency and severity of adverse events, nearly all Grade 1 or 2, and far fewer treatment modifications than competitor regimens Company to host a conference call and webcast today at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN D
- PRORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPCSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it will report combination dose optimization data from the Phase 1b trial of rinzimetostat (ORIC-944) in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Tuesday, March 31, 2026 at 4:30pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call.
- PRORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual MeetingSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts highlighting the potential of rinzimetostat (ORIC-944), a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer, have been accepted for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026 in San Diego, CA. All regular abstracts are available for viewing via AACR's online itinerary planner located here. Poster presentation
- PRORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on March 2, 2026 (the "Grant Date"), ORIC granted a total of 14,800 non-qualified stock options and 2,400 restricted stock units to one new non-executive employee who began their employment with ORIC in February 2026. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stoc
- INSIDERChief Financial Officer Piscitelli Dominic exercised 52,000 shares at a strike of $4.36 and sold $702,686 worth of shares (52,000 units at $13.51) (SEC Form 4)4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
- SECSEC Form 144 filed by Oric Pharmaceuticals Inc.144 - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
- SECSEC Form 8-K filed by Oric Pharmaceuticals Inc.8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
- SECSEC Form 424B5 filed by Oric Pharmaceuticals Inc.424B5 - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
- SECSEC Form S-8 filed by Oric Pharmaceuticals Inc.S-8 - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
- SECSEC Form 10-K filed by Oric Pharmaceuticals Inc.10-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
ORIC FAQ
7 questionsWhat does Oric Pharmaceuticals Inc. do?
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. Its other product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer...Where does ORIC stock trade?
Oric Pharmaceuticals Inc. (ORIC) is listed on NASDAQ.What sector and industry is ORIC in?
Oric Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Oric Pharmaceuticals Inc. go public?
Oric Pharmaceuticals Inc. (ORIC) completed its IPO in 2020.What are analysts saying about ORIC?
Oric Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy with a $1500.00 price target on 2026-05-15. Recent price targets range from $1500.00 to $2500.00.What companies are similar to ORIC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ORIC side-by-side with any of them on Quantisnow.How can I track ORIC on Quantisnow?
Quantisnow aggregates Oric Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ORIC to receive live email and push alerts on every new disclosure.